Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
272 participants
OBSERVATIONAL
2016-04-26
2025-06-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male and female patients, greater than or equal to 18 years of age or age of majority in state of residence.
3. Patients planning to receive Gliadel Wafer, or having already received Gliadel Wafer and having signed consent to enroll in the registry within 14 calendar days after surgery for treatment of central nervous system (CNS) tumor(s), or are currently enrolled in another study where they received Gliadel Wafer.
4. Signed release form, by the patient or a legally acceptable representative, permitting abstraction of the patient's medical records at Baseline and during participation in the registry.
Exclusion Criteria
2. Any abnormality or medical condition that, at the discretion of the Investigator, may put the patient at increased risk by participating in this registry.
3. Any other reason that, in the Investigator's opinion, makes the patient unsuitable to participate in this registry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arbor Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Spine and Neuro Center
Huntsville, Alabama, United States
Borrow Neurological Institute
Phoenix, Arizona, United States
Spine Group Arizona At Honorhealth Scottsdale Osborn Medical Center
Scottdale, Arizona, United States
Neurological Associates of Tucson, DBA Center for Neurosciences
Tucson, Arizona, United States
David Geffen School of Medicine at UCLA; Departments of Neurosurgery and Pathology at the
Los Angeles, California, United States
University of California, San Francisco Department of Neurological Surgery
San Francisco, California, United States
University of Colorado School of Medicine
Aurora, Colorado, United States
Baycare Medical Group
Tampa, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Beacon Medical Group
Elkhart, Indiana, United States
Baptist Health Paducah
Paducah, Kentucky, United States
Oschner Medical Center
New Orleans, Louisiana, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
McLaren Bay Neurology Associates
Bay City, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Depaul Hospital
Bridgeton, Missouri, United States
St. Louis University Hospital
St Louis, Missouri, United States
Western Regional Ctr for Brain and Spine Surgery
Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Jfk Medical Center
Edison, New Jersey, United States
Albany Medical Center Hospital
Albany, New York, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Brain Tumor Center
Lake Success, New York, United States
Crouse Neuroscience Institute
Syracuse, New York, United States
Vidant Medical Center
Greenville, North Carolina, United States
Wake Forest Baptist Med Center
Winston-Salem, North Carolina, United States
Mount Carmel Neurosurgery
Columbus, Ohio, United States
University of Oklahoma - Stevenson Cancer Center
Oklahoma City, Oklahoma, United States
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
Grand Strand Medical Center
Myrtle Beach, South Carolina, United States
University of Washington School of Medicine
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, Ryken T, Johnson T, Scullin E. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 Apr;7(2):CNS08. doi: 10.2217/cns-2017-0036. Epub 2017 Dec 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR22.001
Identifier Type: -
Identifier Source: org_study_id